INHBB and familial pancreatic carcinoma: INHBB promotes tumor progression, and therapeutic inhibition of its receptor with bimagrumab demonstrated effective antitumor responses in diabetic mouse models, suggesting INHBB as a novel therapeutic target for pancreatic cancer comanaged with diabetes.